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Summary
Objective: Aminosugars are commonly used to treat osteoarthritis; however, molecular mechanisms mediating their anti-arthritic activities are
still poorly understood. This study analyzes facilitated transport and metabolic effects of glucosamine (GlcN) and N-acetylglucosamine
(GlcNAc) in human articular chondrocytes.
Methods: Human articular chondrocytes were isolated from knee cartilage. Facilitated transport of glucose, GlcN and GlcNAc was measured
by uptake of [3H]2-deoxyglucose, [3H]GlcN and [3H]GlcNAc. Glucose transporter (GLUT) expression was analyzed by Western blotting. Pro-
duction of sulfated glycosaminoglycans (SGAG) was measured using [35S]SO4. Hyaluronan was quantiﬁed using hyaluronan binding protein.
Results: Chondrocytes actively import and metabolize GlcN but not GlcNAc and this represents a cell-type speciﬁc phenomenon. Similar to
facilitated glucose transport, GlcN transport in chondrocytes is accelerated by cytokines and growth factors. GlcN non-competitively inhibits
basal glucose transport, which in part depends on GlcN-mediated depletion of ATP stores. In IL-1b-stimulated chondrocytes, GlcN inhibits
membrane translocation of GLUT1 and 6, but does not affect the expression of GLUT3. In contrast to GlcN, GlcNAc accelerates facilitated
glucose transport. In parallel with the opposing actions of these aminosugars on glucose transport, GlcN inhibits hyaluronan and SGAG syn-
thesis while GlcNAc stimulates hyaluronan synthesis. GlcNAc-accelerated hyaluronan synthesis is associated with upregulation of hyaluronan
synthase-2.
Conclusion: Differences in GlcN and GlcNAc uptake, and their subsequent effects on glucose transport, GLUT expression and SGAG and
hyaluronan synthesis, indicate that these two aminosugars have distinct molecular mechanisms mediating their differential biological activities
in chondrocytes.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA), characterized by progressive degen-
eration of articular cartilage and clinically manifested in
the form of joint pain and loss of joint function, is the
most prevalent joint disease1,2. Certain aminosugars, in-
cluding glucosamine (GlcN) and N-acetylglucosamine
(GlcNAc) are commonly used by OA patients for symptom
relief3,4. Evaluation of several clinical trials on GlcN indi-
cate that this aminosugar can potentially beneﬁt patients
with knee OA5e8. Recently, we demonstrated that
intraarticular administration of GlcNAc in animals with ex-
perimental OA produces chondroprotective and anti-in-
ﬂammatory effects9.
Molecular mechanisms mediating anti-arthritic activities
of GlcN and GlcNAc are still poorly understood. Binding
to cell surface molecules and transmembranous transport
are the ﬁrst steps in sugar interactions with cells. GlcN
transport is facilitated by glucose transporter proteins or
GLUTs10. Human articular chondrocytes express several
speciﬁc GLUTs, including GLUT1, 3, 6, 8, 10, 11 and
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1022chondrocytes is regulated by pro-inﬂammatory cytokines
and growth factors13. Transport of GlcN and GlcNAc in hu-
man articular chondrocytes has not been analyzed in
detail.
Another important aspect of aminosugar interactions with
chondrocytes is their effect on facilitated glucose transport.
Since glucose serves as the main precursor for extracellular
matrix glycosaminoglycan synthesis and as the main en-
ergy source14e17, changes in facilitated glucose transport
and glucose inﬂux can have profound effects on chondro-
cyte homeostasis.
The present work describes molecular mechanisms con-
trolling transmembranous transport of GlcN and GlcNAc,
and identiﬁes effects of these aminosugars on facilitated
glucose transport, GLUT expression and glycosaminogly-
can synthesis in human articular chondrocytes.MethodsCELL CULTURENormal human knee joints were obtained from tissue banks from donors
without history of joint disease. Knee cartilage was also obtained from OA
patients at the time of total joint replacement surgery. All tissue samples
were graded according to a modiﬁed Mankin scale18. Articular cartilage
was harvested from femoral condyles and tibial plateaus. Chondrocytes
were isolated from the cartilage by collagenase digestion and maintained
in high-density monolayer cultures in DMEM containing 10% calf serum.
Experiments in this study were performed with ﬁrst passage cells.
1023Osteoarthritis and Cartilage Vol. 17, No. 8MEASUREMENT OF SUGAR TRANSPORTFacilitated transport of glucose, GlcN and GlcNAc was measured by up-
take of [3H]2-deoxyglucose, [3H]GlcN and [3H]GlcNAc, respectively. Mea-
surement of [3H]GlcN and [3H]GlcNAc transport was performed utilizing the
[3H]2-deoxyglucose uptake protocol12 with time points as indicated for
each data set. Chondrocytes were plated in 24-well plates at 5 104 cells/
well in high glucose DMEM containing 10% calf serum for 24 h at 37 C. Cul-
ture media were replaced with serum-free, glucose- and pyruvate-free
DMEM containing 10 mCi/ml [3H]-sugar (250 ml/well) and speciﬁc test agents.
Plates were incubated at room temperature for the time intervals indicated.
Subsequently, the media were aspirated and cells were washed three times
with cold PBS. The cells were lysed with 400 ml/well Cell Death Lysis buffer
(Roche Diagnostics, Indianapolis, IN) for 15 min. A total of 300 ml of cell ly-
sate was transferred to scintillation vials, and the radioactivity was deter-
mined by scintillation counting. All experiments were performed in triplicate
with at least four different chondrocyte donors.ISOLATION OF BASOLATERAL MEMBRANES AND WESTERN
IMMUNOBLOTTINGIsolation of chondrocyte basolateral membranes and Western immuno-
bloting were performed according to previously published protocols12,13.
Brieﬂy, conﬂuent cultures of chondrocytes in six-well plates were washed
three times with cold PBS and twice with cold lysis buffer (2.5 mM imidazole,
pH 7, containing protease inhibitor mixture; SigmaeAldrich), and were al-
lowed to swell in the same buffer for 1 h at 4 C. Cells were then disrupted
with a forceful spray of cold lysis buffer through a blunt needle. The lysates
were decanted, and the attached basolateral membranes were washed three
times with cold lysis buffer. The basolateral membranes attached to the wells
were detached with a cell lifter (Fisher, Pittsburgh, PA) in cold lysis buffer.
Finally, the membranes were collected by centrifugation at 20,000g for
15 min. Western blotting was performed with antibodies to human GLUT1,
3 and 6 (Alpha Diagnostic International, San Antonio, TX).ATP MEASUREMENTMeasurement of the intracellular ATP was performed according to a previ-
ously published protocol19.HYALURONIC ACID MEASUREMENTConcentration of hyaluronic acid in cell culture supernatants was mea-
sured using hyaluronan binding protein [HA test kit, Corgenix, Westminster,
CO] according to the manufacturer’s protocol.METABOLIC LABELING OF CHONDROCYTES WITH [35S]SO4Production and accumulation of sulfated glycosaminoglycans (SGAG)
were measured using radioactive [35S]SO4
20. Brieﬂy, cells were plated in
24-well plates and incubated for 24 h. Test agents were then added in 2%
low glucose DMEM and incubated for 24 h before addition of [35S]SO4
(20 mCi/ml) and incubation for an additional 24 h. After incubation, the culture
supernatants were harvested and SGAG precipitated with dimethyl methy-
lene blue. Simultaneously, cell-associated SGAG were extracted with 4 M
guanidine chloride and precipitated with 5% potassium acetate in ethanol.
The measurement of [35S]SO4 incorporation was performed for the combined
free and cell-associated fraction of the SGAG.STUDIES WITH SIGNALING INHIBITORSThe following inhibitors were used at the concentrations shown in paren-
theses: PD98059 (10 mM), SP600125 (2 mM), SB202190 (10 mM), Ro318220
(10 mM), wortmannin (20 nM) and alloxan (5 mM). Cells were incubated with
the inhibitors in low glucose DMEM with 2% calf serum and then GlcN and
[3H]2-deoxyglucose were added, and uptake was measured as above.RT-PCRChondrocytes were stimulated with 10 mM GlcNAc for 24 h. RNA was
isolated with the RNeasy kit (Qiagen, Valencia, CA), and cDNA was pre-
pared with Superscript II RNase H-reverse transcriptase (Life Technolo-
gies, Rockville, MD). The sequence of the HAS-2 sense primer was
TTTCTTTATGTGACTCATCTGTCTCACCGG, the antisense primer e
ATTGTTGGCTACCAGTTTATCCAAACGG. The following PCR conditions
were used: 95 C for 3 min, followed by 27 cycles of 45 s at 95 C, 45 s
at 60 C, and 1 min at 72 C. The PCR products were separated by electro-
phoresis in 1.5% agarose gels and visualized with ethidium bromide stain.
Parallel ampliﬁcation of cDNA for the housekeeping gene GAPDH wasused as a control (sense primer e TGGTATCGTGGAAGGACTCATG;
antisense pimer e ATGCCAGTGAGCTTCCCGTTCAG).REAGENTS[3H]2-Deoxyglucose (2DG), [3H]GlcN and [Acetyl-3H]GlcN were pur-
chased from ICN (Costa Mesa, CA). [1-3H]GlcNAc was purchased from
Amersham (Piscataway, NJ). PD98059 was purchased from Calbiochem
(La Jolla, CA). Ro 31-8220, SP600125 and SB202190 were purchased
from Biomol (Plymouth Meeting, PA). Wortmannin, alloxan and tunicamycin
were purchased from Sigma (St. Louis, MO). Human recombinant IL-1b was
obtained from the National Cancer Institute (Bethesda, MD). Human re-
combinant TGFb1 was purchased from Austral Biologicals (San Ramon,
CA). Antibodies to human GLUT1, 3 and 6 were purchased from Alpha
Diagnostic International (San Antonio, TX).STATISTICAL ANALYSISStatistical analysis was performed using Student’s t-test in Excel Analysis
ToolPack (Microsoft, Redmond, WA).ResultsFACILITATED TRANSPORT OF GlcN AND GlcNAc IN HUMAN
ARTICULAR CHONDROCYTESFacilitated transport of GlcN and GlcNAc in chondrocytes
was measured by [3H]GlcN and [3H]GlcNAc uptake, re-
spectively. Chondrocytes actively import GlcN in a time-de-
pendent fashion while the transport of GlcNAc is not
statistically signiﬁcant [Fig. 1(A)]. Internalization of
[3H]GlcNAc was not detectable even after 24 h. The uptake
of GlcN in chondrocytes is of similar magnitude as in syno-
vial ﬁbroblasts. It is higher in normal BJ skin ﬁbroblasts
[Fig. 1(B)]. Tumor cell lines such as SW1353 or 293
[Fig. 1(B)] and Hela or HepG2 (not shown) internalize
even larger amounts of GlcN. The absence of [3H]GlcNAc
transport in chondrocytes represents a cell-type-speciﬁc
phenomenon since several other cell types, including 293
human embryonic kidney cells, BJ normal human foreskin
ﬁbroblasts and HepG2 human hepatoma cells actively
transported this acetylated aminosugar [Fig. 1(C)]. There
were no differences between transmembranous transport
of [1-3H]GlcNAc and [Acetyl-3H]GlcNAc, indicating that po-
tential deacetylation of GlcNAc is not the mechanism ex-
plaining the results described above. Treatment of
chondrocytes with tunicamycin, an inhibitor of protein N-gly-
cosylation and GLUT N-glycosylation in particular12, had no
effects on GlcNAc import (not shown), suggesting that gly-
cosylation of GLUTs is not responsible for the absence of
GlcNAc transport in chondrocytes.
Since GlcN is a positively charged molecule, it was possi-
ble that themeasuredGlcN transport could be an artifact sec-
ondary to its non-speciﬁc interactions with negatively
charged glycosaminoglycans surrounding the chondrocytes.
To address this issue, chondrocytes were treated with hyal-
uronidase plus chondroitinase ABC followed by the mea-
surement of [3H]GlcN uptake. Treatment of chondrocytes
with these enzymes did not inﬂuence [3H]GlcN uptake.
Based on the differences between GlcNAc and GlcN
transport in chondrocytes, we examined whether these
two aminosugars also have distinct patterns of intracellular
utilization. We compared incorporation of [3H]GlcN versus
[3H]GlcNAc into sulfated glycosaminoglycans which reﬂects
the intracellular ﬂux of these aminosugars through the hex-
osamine pathway21. In agreement with the transport data,
GlcN was actively incorporated into SGAG (in both control
and TGFb-stimulated chondrocytes) while GlcNAc was
not (data not shown).
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Fig. 1. Facilitated transport of GlcN and GlcNAc in human articular chondrocytes and other cell types. A. Time course of [3H]GlcN and
[3H]GlcNAc uptake in chondrocytes. Facilitated transport of GlcN and GlcNAc in human normal articular chondrocytes was measured by
[3H]GlcN and [3H]GlcNAc uptake, respectively. Chondrocytes actively import GlcN in a time-dependent fashion. The import of GlcNAc is
not statistically signiﬁcant. Cell-type speciﬁcity of GlcN (B) and GlcNAc transport (C). Facilitated transport of GlcN and GlcNAc was measured
by [3H]GlcN and [3H]GlcNAc uptake, respectively, after 30 min incubation with the labeled sugars. The following cell types were used: HC e
normal human chondrocytes; SFB e normal human synovial ﬁbroblasts; SW1353 e human chondrosarcoma cells; 293 e human embryonic
kidney; BJ e normal human foreskin ﬁbroblasts.
1024 A. R. Shikhman et al.: Effects of aminosugars on chondrocytesTaken together, these data indicate that GlcN but not
GlcNAc is actively imported and metabolized by
chondrocytes.EFFECTS OF GlcN AND GlcNAc ON FACILITATED GLUCOSE
TRANSPORT IN CHONDROCYTESGlcN inhibits facilitated glucose transport in insulin-sensi-
tive cells, including muscle cells and adipocytes and in-
duces glucose intolerance19,22. The effect of GlcN on
facilitated glucose transport in non-insulin sensitive cells
has been studied insufﬁciently. Furthermore, the effect of
GlcNAc on this process is unknown.
Incubation of chondrocytes with GlcN resulted in a non-
competitive and dose dependent inhibition of facilitatedglucose transport. In contrast, GlcNAc stimulated glucose
transport within a narrow range of concentrations (Fig. 2).
To address effects of aminosugars on GLUT expression
Western blotting was performed. GlcN reduced GLUT1
and 6 protein incorporation into plasma membrane in both
unstimulated and IL-1b-stimulated chondrocytes but did
not change the expression of non-cytokine regulated
GLUT3 (Fig. 3). GlcNAc had no effects on GLUT expres-
sion (not shown).
To determine signaling mechanisms mediating the inhib-
itory effects of GlcN on glucose transport in chondrocytes
we analyzed MAP kinases, protein kinase C, PI-3/Akt ki-
nase and O-GlcNAc transferase, since they have been
shown to regulate glucose transport23e26. Inhibition of
MAP kinases [PD98059 for ERK27, SP600125 for JNK27
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Fig. 2. GlcN but not GlcNAc inhibits facilitated glucose transport.
Normal human chondrocytes were treated with GlcN or GlcNAc
for 4 h followed by measurement of facilitated glucose transport
([3H]2DG uptake). [3H]2DG uptake in unstimulated chondrocytes
was considered as 100%. *P< 0.05.
0
20
40
60
80
100
120
140
0 5 10 15 20 25
mM
GlcN
GlcNAc
 *
*
Fig. 4. GlcN depletes intracellular ATP. Chondrocytes incubated in
DMEM containing 2% serum and 5 mM Glc were treated with var-
ious concentrations of GlcN or GlcNAc for 4 h followed by measure-
ment of intracellular ATP. Concentration of ATP in untreated
chondrocytes was 1.7þ/0.8 mM per 5 106 cells, and it was con-
sidered as 100%. *P< 0.05.
1025Osteoarthritis and Cartilage Vol. 17, No. 8and SB202190 for p38 MAP kinase27], PKC [Ro31822027],
PI-3-kinase [wortmannin27] and O-GlcNAc-transferase [al-
loxan28] did not restore GlcN-suppressed glucose transport
(not shown).
GlcN depleted the ATP pool in chondrocytes (Fig. 4).
Due to the reported connection between ATP depletion
and inhibition of glucose transport19, we analyzed whether
restoration of ATP pool would inﬂuence GlcN-inhibited
glucose transport. Co-incubation of chondrocytes with
GlcN and increased concentrations of glucose or inosine
[inosine increases ATP concentration via formation of
ribose 5-phosphate and subsequent conversion to 3-
phosphoglyceraldehyde, which enters the glycolytic path-
way to generate ATP19] partially restored GlcN-inhibited
glucose transport (data not shown).
In summary, GlcN inhibited glucose transport in chondro-
cytes via mechanisms involving ATP depletion andctrl IL-1 GlcN IL-1+GlcN
GLUT1
GLUT6
GLUT3
Fig. 3. GlcN inhibits plasma membrane incorporation of GLUT1 and
6. Chondrocytes were stimulated with IL-1b (1 ng/ml) with or with-
out GlcN (10 mM) for 24 h. Detection of GLUT1, 3 and 6 proteins
in the chondrocyte plasma membranes was performed using West-
ern blotting. Unstimulated chondrocytes were used as control.independent from activation of MAP kinases, PKC, PI-3-
kinase and O-GlcNAc transferase. GlcNAc is not imported
by chondrocytes but is capable of accelerating glucose
transport.DIFFERENTIAL EFFECTS OF GlcN AND GlcNAc ON
GLYCOSAMINOGLYCAN SYNTHESISGlucose serves not only as the key energy source in
chondrocytes but also as the main precursor for glycosami-
noglycan synthesis16. To analyze the effect of exogenous
aminosugars on glycosaminoglycan synthesis, human artic-
ular chondrocytes were incubated with either GlcN or
GlcNAc followed by the measurement of hyaluronic acid
production using an assay with hyaluronan binding protein
and sulfated glycosaminoglycan synthesis (metabolic label-
ing with [35S]SO4). GlcN inhibited synthesis of SGAG and
hyaluronic acid at 5 and 10 mM concentrations. In contrast,
GlcNAc did not inhibit SGAG synthesis, and stimulated hy-
aluronic acid production at 10 mM concentration (Fig. 5).
We did not observe any effects of GlcN and GlcNAc on gly-
cosaminoglycan or hyaluronic acid synthesis in human
chondrocytes at nano- and micromolar concentrations (not
shown). GlcNAc-accelerated production of hyaluronan
was associated with the induction of HAS-2 (Fig. 6), a key
enzyme in hyaluronan synthesis29.
Therefore, the different effects of GlcN and GlcNAc on
facilitated glucose transport parallel the differences in their
effects on glycosaminoglycan synthesis. Since glycosami-
noglycans represent essential structural elements of the
cartilage extracellular matrix and chondrocyte pericellular
matrix, the stimulatory effect of GlcNAc on GAG synthesis
can be considered as one the beneﬁcial events contributing
to its chondroprotective activity in vivo9.
Discussion
Facilitated transport of sugars is the ﬁrst rate-limited step
in their metabolism. It has been demonstrated that
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Fig. 5. Different effects of GlcN and GlcNAc on sulfated glycosami-
noglycan (SGAG) (A) and HA (B) synthesis. A. SGAG synthesis
was measured by metabolic labeling of normal and OA human
knee chondrocytes with [35S]SO4. Chondrocytes were incubated
with either GlcN or GlcNAc in DMEM containing 5 mM glucose
and 2% serum for 24 h followed by the metabolic labeling with
[35S]SO4 in the presence of the aminosugars. [
35S]SO4 incorpora-
tion in untreated chondrocytes was considered as 100%. B.
Chondrocytes were treated with either GlcN or GlcNAc in DMEM
containing 5 mM glucose and 2% serum for 72 h. Hyaluronan
(HA) concentration in chondrocyte supernatants was measured
using an assay with hyaluronan binding protein. HA concentration
in untreated chondrocytes was considered as 100%.
ctrl GlcNAc 
HAS-2
GAPDH
Fig. 6. GlcNAc increases expression of HAS-2 in human articular
chondrocytes. Normal human articular chondrocytes were stimu-
lated with 10 mM GlcNAc for 24 h. Expression of HAS-2 mRNA
was analyzed by RT-PCR.
1026 A. R. Shikhman et al.: Effects of aminosugars on chondrocytestransmembranous transport of GlcN is facilitated by
GLUTs10. GLUTs are rather different in their afﬁnity toward
GlcN. For example, GLUT2 has 20-times higher afﬁnity to-
ward GlcN than GLUT1 and 410. Respectively, the rate
and kinetics of GlcN uptake depend on the combination
and abundance of GLUTs expressed in a given cell-type.
The present study shows that in contrast to GlcN, GlcNAc
is not internalized and metabolized by chondrocytes, and
this represents a cell-type-speciﬁc phenomenon. Low rates
of transmembranous transport of acetylated aminosugars
compared to their non-acetylated derivatives were previ-
ously described in brain synaptosomes30.
Chondrocyte exposure to low millimolar concentrations of
GlcN results in inhibition of basal, cytokine- and growthfactor-stimulated glucose transport, which in part depends
on GlcN-mediated depletion of ATP stores. In insulin-sensi-
tive cells, effector mechanisms regulating GlcN-inhibited
glucose transport include suppression of insulin-regulated
GLUT4 translocation to the cell surface32. Parenteral ad-
ministration of GlcN also results in insulin resistance and
suppressed GLUT4 translocation to the cell membrane in
skeletal muscle cells31. Additionally, GlcN inhibits plasma
membrane incorporation of the ubiquitously expressed
GLUT119. In chondrocytes, downstream events mediating
the inhibitory effect of GlcN on glucose transport are asso-
ciated with suppression of basal and IL-1b-stimulated
plasma membrane incorporation of GLUT1 and 6.
In contrast to GlcN, GlcNAc accelerates facilitated glu-
cose transport without affecting membrane incorporation
of GLUTs. Due to the fact that GlcNAc is poorly transported
into the intracellular compartment but interacts with GLUTs,
it is possible that interactions between GLUTs and GlcNAc
affect their afﬁnity for glucose. The observed effects of
GlcNAc on chondrocyte function are possibly related to
binding of GlcNAc to GLUTs in a receptoreligand interac-
tion that generates intracellular signaling events that
change IL-1 responses or alter the synthesis of extracellular
matrix components.
Chondrocytes function under anaerobic conditions and
utilize glucose as the main energy substrate and precur-
sor for glycosaminoglycan synthesis16,21,32,33; conse-
quently, aminosugar-induced changes in facilitated
glucose transport may have profound effects on extracel-
lular matrix homeostasis. Similar to their effects on glu-
cose transport, GlcN inhibited and GlcNAc stimulated
hyaluronan and sulfated glycosaminoglycan synthesis. A
prior study reported that GlcN at 1 mM did not alter gly-
cosaminoglycan synthesis, aggrecan or HAS-2 levels34.
The observations on glycosaminoglycan synthesis are
identical to those in the present study which also showed
that higher (5 and 10 mM) concentrations of GlcN have in-
hibitory effects. Short term incubation of chondrocytes
with GlcN also did not increase intracellular concentra-
tions of nucleotide-activated sugars required for GAG
synthesis35.
In the past, different experimental approaches have
been used to determine the effect of GlcN on cartilage ex-
tracellular matrix synthesis. Previously published36 and our
present data indicate that GlcN is imported by cells and in-
corporated into newly synthesized glycosaminoglycans
UDP-N-acetylhexosamines, the end products of the hexos-
amine pathway and the precursors for glycosaminoglycan
synthesis21. Sweeney et al. showed that in Swarm rat
chondrosarcoma cells only 1 in 375 of the UDP-N-acetyl-
hexosamines is derived from the exogenous GlcN in the
1027Osteoarthritis and Cartilage Vol. 17, No. 8presence of glucose17. In contrast, Noyszewski et al. dem-
onstrated that GlcN is preferentially incorporated into ga-
lactosamine moieties of chondroitin sulfate at levels that
were 300% higher than the equivalent amount of glu-
cose37. Bassleer et al. reported that GlcN sulfate at low
and medium micromolar concentrations accelerated the
production of proteoglycans in cultured human articular
chondrocytes without affecting the length of glycosamino-
glycan chains and the rate of DNA and collagen II synthe-
sis38. Mroz and Silbert showed that at submillimolar
concentrations GlcN had no effect on SGAG synthesis
whereas high concentrations of GlcN inhibited this pro-
cess39. Similar ﬁndings were published by De Mattei
et al.40. These variations among the experimental results
most likely reﬂect the fact that GlcN plays a dual role in
cell physiology: it efﬁciently enters the hexosamine path-
way by bypassing glutamine:fructose 6-phosphate amido-
transferase, a gate-keeping enzyme of the hexosamine
pathway, and enters the pool of UDP-N-acetylhexos-
amines41; however, it also inhibits facilitated glucose trans-
port42 and, thus, can potentially decrease glucose ﬂux
through the hexosamine pathway. Therefore, the global ef-
fect of GlcN on glycosaminoglycan synthesis depends on
the dominance of one of these two processes.
The concentrations of GlcNAc (1e20 mM) used in the in
vitro experiments with chondrocytes cannot be achieved
after oral administration. The levels of GlcN in the joint after
oral administration are approximately 10 mM43. The pur-
pose of the present study was to analyze potential mecha-
nisms and effects of the aminosugars when injected
intraarticularly. In previous studies GlcNAc was injected
at doses as high as 1 M into rabbit joints and this resulted
in beneﬁcial structure-modifying effects9. Thus, the concen-
trations used in the present study are clearly within the
range that can be reached after direct administration into
the joint.
In conclusion, GlcN but not GlcNAc is actively imported
and metabolized by human articular chondrocytes. At low
millimolar concentrations GlcN inhibits while GlcNAc stimu-
lates facilitated glucose transport. GlcN inhibits sulfated
glycosaminoglycan synthesis but GlcNAc increases HA
levels and this is related to increased HAS-2 expression.
GlcN-inhibited glucose transport is associated with sup-
pressed membrane incorporation of GLUT1 and 6 proteins.
Thus, identiﬁed differences in GlcN and GlcNAc uptake
and their effects on glucose transport and metabolism in
chondrocytes indicate that these two aminosugars have
distinct molecular mechanisms mediating their biological
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